drugset / Trial / NCT01944969

Long-term Safety and Tolerability Study of Brexpiprazole as Adjunctive Treatment in Patients With Major Depressive Disorder

NCT01944969

NaSingle-groupOpen-labelTreatment

Summary

To evaluate the long-term safety and tolerability of brexpiprazole as adjunctive treatment in patients with Major Depressive Disorder (MDD)

Timeline

Start
2013-10
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Brexpiprazole Small molecule 1 mg Oral
Subject Brexpiprazole Small molecule 2 mg Oral
Subject Brexpiprazole Small molecule 3 mg Oral